Types of oral contrast agents with positive signal enhancement:
Ideal oral contrast agents are immiscible with water, biologically inert, have a low viscosity and surface tension. Oral positive contrast agents may improve the separation of bowel loops, the detection of polyps in colon MRI or the assessment of inflammatory bowel in the small intestine. Several positive oral contrast agents are available and they are safe to use, for example gadolinium solution, ferric ammonium citrate, different oil emulsions and pediatric formula.
Unfavorably motion artifacts caused by respiration and peristalsis may be increased in MR imaging. In addition, the signal of the positive contrast medium may decrease caused by dilution in gastrointestinal (GI) secretions. With the use of contrast agents that are immiscible with water, no dilution and accompanying signal loss occur even when the contrast agent is in contact with the intraluminal contents of the GI tract. Another disadvantage may be residual substances in the bowel, resembling masses when enclosed by bright signal. In addition, positive contrast agents may have a similar signal as bright masses, which make their (e.g. lipoma) detection difficult.

See also Gastrointestinal Paramagnetic Contrast Agents, Combination Oral Contrast Agents, Gastrointestinal Diamagnetic Contrast Agents.

Contrast agents are chemical substances introduced to the anatomical or functional region being imaged, to increase the differences between different tissues or between normal and abnormal tissue, by altering the relaxation times. MRI contrast agents are classified by the different changes in relaxation times after their injection.
The design objectives for the next generation of MR contrast agents will likely focus on prolonging intravascular retention, improving tissue targeting, and accessing new contrast mechanisms. Macromolecular paramagnetic contrast agents are being tested worldwide. Preclinical data shows that these agents demonstrate great promise for improving the quality of MR angiography, and in quantificating capillary permeability and myocardial perfusion.
Ultrasmall superparamagnetic iron oxide (USPIO) particles have been evaluated in multicenter clinical trials for lymph node MR imaging and MR angiography, with the clinical impact under discussion. In addition, a wide variety of vector and carrier molecules, including antibodies, peptides, proteins, polysaccharides, liposomes, and cells have been developed to deliver magnetic labels to specific sites. Technical advances in MR imaging will further increase the efficacy and necessity of tissue-specific MRI contrast agents.

See also Adverse Reaction and Nephrogenic Systemic Fibrosis.

See also the related poll result: 'The development of contrast agents in MRI is'

(FRE) Flow related enhancement could be seen most for blood flow, but also for other liquids with some MR imaging techniques, as an increase in intensity due to the washout of saturated spins. FRE provides positive contrast ("bright blood") of vascular details in time of flight MRA as well as the physiologic characterization of blood flow.
If stationary spins within the scanned region experience only an incomplete T1 relaxation between the repeated radio frequency (RF) excitations, this results in fewer signal of the stationary tissue (compared to inflowing blood with completely relaxed spins). The degree of the flow related enhancement is proportional to the blood flow velocity and the used repetition time. The use of flow compensation (gradient moment nulling) improves the FRE especially in gradient echo sequences.

ABLAVAR™ (formerly named Vasovist™) is a blood pool agent for magnetic resonance angiography (MRA), which opens new medical imaging possibilities in the evaluation of aortoiliac occlusive disease (AIOD) in patients with suspected peripheral vascular disease.
ABLAVAR™ binds reversibly to blood albumin, providing imaging with high spatial resolution up to 1 hour after injection, due to its high relaxivity and to the long lasting increased signal intensity of blood.
As with other contrast media: the possibility of serious or life-threatening anaphylactic or anaphylactoid reactions, including cardiovascular, respiratory and/or cutaneous manifestations, should always be considered.

WARNING:
NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m²), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.

See also Cardiovascular Imaging, Adverse Reaction, Molecular Imaging, and MRI Safety.

Artirem®, the arthrography-specific contrast agent for MRI is a dilute form of Dotarem® with a less concentration of Gd (1:200). Artirem® has to be injected directly into the joints for better visualization and delimitation, of the ligament and tendon structures in particular.